BACKGROUND: Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. OBJECTIVE/ METHODS: this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. RESULTS/ CONCLUSION: An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.
BACKGROUND:Adrenocortical carcinoma (ACC) is an extremely rare aggressive disease. Few data are available on the efficacy of systemic antineoplastic treatments (mitotane and cytotoxic therapy) in the treatment of advanced disease. OBJECTIVE/ METHODS: this paper will review the existing treatment strategies and new perspectives in the management of ACC patients. RESULTS/ CONCLUSION: An ongoing randomized international trial aims to define the best combination chemotherapy plus mitotane regimen. Based on the results of a case control study, mitotane is being explored as adjuvant therapy. Genetic and biological studies have identified molecular targets for specific targeted drugs such as IGF receptor inhibitors and antiangiogenetic drugs. Phase II trials are exploring the activity of these drugs either alone or in combination with chemotherapy.
Authors: Lyndal J Tacon; Ruth S Prichard; Patsy S H Soon; Bruce G Robinson; Roderick J Clifton-Bligh; Stan B Sidhu Journal: Oncologist Date: 2011-01-06
Authors: A Ferrero; P Sperone; A Ardito; G Rossi; S Del Buono; A M Priola; S Bracarda; E Taberna; M Terzolo; A Berruti Journal: J Endocrinol Invest Date: 2012-04-05 Impact factor: 4.256
Authors: J S Ross; K Wang; J V Rand; L Gay; M J Presta; C E Sheehan; S M Ali; J A Elvin; E Labrecque; C Hiemstra; J Buell; G A Otto; R Yelensky; D Lipson; D Morosini; J Chmielecki; V A Miller; P J Stephens Journal: J Clin Pathol Date: 2014-07-30 Impact factor: 3.411